Verona Pharma plc Verona Pharma To Announce Financial Results For Second Quarter Ended June 30, 2019 And Provide Clinical Dev...

 
TIDMVRP 
 
   LONDON, July 30, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, today announces that it will 
report its audited financial results for the second quarter ended June 
30, 2019 on Tuesday, August 6, 2019. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) on Tuesday, 
August 6, 2019 to discuss the second quarter financial results and 
provide a clinical development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 7433729 and dialing the following numbers: 
 
 
   -- 866-940-4574 or 409-216-0615 for callers in the United States 
 
   -- 0800 028 8438 for callers in the United Kingdom 
 
   -- 0800 181 5287 for callers in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at 
https://www.globenewswire.com/Tracker?data=HyaZGEKOtaYAY6gExsw9IMjggqbzj9ihoU8OmdPEMSlaCbm3VdVDMp1YBHNOuDBUyhklfyrEgY5TtOzsNI5Bwb-SOMVcyQkGY-pWUizAAz0= 
www.veronapharma.com and clicking on the "Events and presentations" 
link. 
 
   A webcast replay of the conference call (audio) will be available for 30 
days on the "Investors" page of Verona Pharma's website at 
https://www.globenewswire.com/Tracker?data=HyaZGEKOtaYAY6gExsw9IBx1AY5hyOuuNVwT-ZSNCaLFLlLvIvWFgEy2ikTm_O8rbpI4xLcPwT2K3HZVDrjUqHaBVioV27lUh4B2fgyujN4= 
www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, 
inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that 
has been shown to act as both a bronchodilator and an anti-inflammatory 
agent in a single compound. Nebulized ensifentrine is currently in Phase 
2b clinical development for the maintenance treatment of COPD and is 
planned to enter Phase 3 trials for this indication in 2020. Verona 
Pharma plans a targeted US launch of the nebulized formulation, which is 
expected to benefit from a simplified Medicare Part B reimbursement 
process in the US. Verona Pharma may also develop ensifentrine for the 
treatment of cystic fibrosis and asthma. 
 
   Ensifentrine has shown significant and clinically meaningful 
improvements in both lung function and COPD symptoms, including 
breathlessness, in prior Phase 2 clinical studies in patients with 
moderate-to-severe COPD. In addition, ensifentrine has further improved 
lung function and reduced lung volumes in patients taking standard 
short- and long-acting bronchodilator therapy, including maximum 
bronchodilator treatment with dual/triple therapy. Ensifentrine has been 
well tolerated in clinical trials involving more than 800 people to 
date. 
 
   Forward Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, statements regarding  the development 
plans for ensifentrine, the timing of Phase 3 trials of nebulized 
ensifentrine, the value of the COPD market, the potential of 
ensifentrine as a promising first-in-class treatment option for COPD and 
the availability of Medicare reimbursement. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts and 
the completion of our Phase 2b trial; we may not be successful in 
developing ensifentrine for multiple indications; our ability to obtain 
approval for and commercialize ensifentrine in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; material differences between our "top-line" data and final 
data; our reliance on third parties, including clinical investigators, 
manufacturers and suppliers, and the risks related to these parties' 
ability to successfully develop and commercialize ensifentrine; and 
lawsuits related to patents covering ensifentrine and the potential for 
our patents to be found invalid or unenforceable. These and other 
important factors under the caption "Risk Factors" in our Annual Report 
on Form 20-F filed with the Securities and Exchange Commission ("SEC") 
on March 19, 2019, and our other reports filed with the SEC, could cause 
actual results to differ materially from those indicated by the 
forward-looking statements made in this press release. Any such 
forward-looking statements represent management's estimates as of the 
date of this press release. While we may elect to update such 
forward-looking statements at some point in the future, we disclaim any 
obligation to do so, even if subsequent events cause our views to 
change. These forward-looking statements should not be relied upon as 
representing our views as of any date subsequent to the date of this 
press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                         Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer              info@veronapharma.com 
 
N+1 Singer                                                Tel: +44 (0)20 3283 4200 
 (Nominated Adviser and UK Broker) 
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance) 
 Mia Gardner (Corporate Broking) 
 
Optimum Strategic Communications                          Tel: +44 (0)203 950 9144 
 (European Media and Investor enquiries)                   verona@optimumcomms.com 
Mary Clark, Anne Marieke Ezendam, Hollie Vile 
 
 Westwicke, an ICR Company                                 Tel. +1 646-277-1282 
 (US Investor enquiries)                                   Stephanie.Carrington@icrinc.com 
Stephanie Carrington
(END) Dow Jones Newswires
July 30, 2019 02:00 ET (06:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024